Project Details
Description
To demonstrate that PPi deficiency can serve as a biomarker for patients with calcinosis, or patients who may be destined to develop calcinosis due to their rheumatic diseases including scleroderma spectrum disorders.
| Status | Finished |
|---|---|
| Effective start/end date | 11/5/18 → 4/11/22 |
Funding
- Scleroderma Clinical Trials Consortium Inc. (AGMT 1/11/19)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.